Tumor-suppressor genes (TSGs) have been classically defined as genes whose loss of function in tumor cells contributes to the formation and/or maintenance of the tumor phenotype. TSGs containing nonsense mutations may not be expressed because of nonsense-mediated RNA decay (NMD). We combined inhibition of the NMD process, which clears transcripts that contain nonsense mutations, with the application of high-density single-nucleotide polymorphism arrays analysis to discriminate allelic content in order to identify candidate TSGs in five breast cancer cell lines. We identified ARID1A as a target of NMD in the T47D breast cancer cell line, likely as a consequence of a mutation in exon-9, which introduces a premature stop codon at position Q944. ARID1A encodes a human homolog of yeast SWI1, which is an integral member of the hSWI/SNF complex, an ATPdependent, chromatin-remodeling, multiple-subunit enzyme. Although we did not find any somatic mutations in 11 breast tumors, which show DNA copy-number loss at the 1p36 locus adjacent to ARID1A, we show that low ARID1A RNA or nuclear protein expression is associated with more aggressive breast cancer phenotypes, such as high tumor grade, in two independent cohorts of over 200 human breast cancer cases each. We also found that low ARID1A nuclear expression becomes more prevalent during the later stages of breast tumor progression. Finally, we found that ARID1A reexpression in the T47D cell line results in significant inhibition of colony formation in soft agar. These results suggest that ARID1A may be a candidate TSG in breast cancer.
Introduction
Cancers occur as a result of dysregulation in the function of oncogenes and tumor-suppressor genes (TSGs). TSGs have been classically defined as genes whose loss of function in tumor cells contributes to the formation and/or maintenance of the tumor phenotype (Presneau et al., 2003) . Various mechanisms of inactivation of TSGs have been reported and can include deletion of one allele through chromosomal nondysjunction and/or intra-chromosomal rearrangement, and mutational inactivation of the remaining allele (Presneau et al., 2003) . TSGs have been identified in cancer both as a result of a search for germline mutations in hereditary cancers and the molecular characterization of somatic deletions and mutations in tumor tissue RNA and DNA (Vogelstein and Kinzler, 2004) . However, TSGs containing nonsense mutations may not be detectable using RNA-based next-generation re-sequencing because RNA containing such aberrant transcripts is eliminated by the nonsensemediated RNA decay process (NMD) (Noensie and Dietz, 2001) . Indeed, an interesting strategy to discover potential TSG candidates was elaborated by Noensie and Dietz (2001) and adapted by Huusko et al. (2004) . Noensie and Dietz (2001) proposed that it would be possible to discover nonsense mutation containing mRNA by inhibiting the NMD process. In this way, transcripts containing nonsense mutations are stabilized and selectively increase in quantity relative to nonmutated transcripts. Huusko et al. (2004) then combined NMD inhibition with array comparative genomic hybridization (aCGH) in order to enrich for the selection of candidates mapping to deleted regions in prostate cancer cell lines, thereby identifying EPHB2 as a novel candidate TSG in prostate cancer.
We have adapted the approach of Huusko et al. by integrating the allelic content inferred from high-density genotyping single-nucleotide polymorphism (SNP) arrays to identify candidates TSGs in five breast cancer cell lines. Here we report the discovery of ARID1A as a candidate TSG in the T47D breast cancer cell line by using this approach. ARID1A encodes a human homolog of yeast SWI1, which contains a DNA-binding motif (AT-rich interactive domain, ARID) and is an integral member of the hSWI/SNF complex, an ATPdependent, chromatin-remodeling, multiple-subunit enzyme (Takeuchi et al., 1997 (Takeuchi et al., , 1998 Dallas et al., 1998 Dallas et al., , 2000 Wang et al., 2004; Wilsker et al., 2004; Patsialou et al., 2005) . An increasing body of evidence has demonstrated that SWI/SNF complexes have important roles in gene regulation (Winston and Carlson, 1992; Carlson and Laurent, 1994; Hirschhorn et al., 1995; Kennison, 1995; Sudarsanam et al., 1999 Sudarsanam et al., , 2000 , cell proliferation (Nagl et al., 2005 (Nagl et al., , 2006 (Nagl et al., , 2007 and development (Carlson and Laurent, 1994; Kennison, 1995) . Several genes encoding hSWI/SNF components have been associated with tumorigenesis (Medina and Sanchez-Cespedes, 2008; Roberts and Biegel, 2009; Rodriguez-Nieto and Sanchez-Cespedes, 2009 ). Moreover, Huang et al. (2007) reported that an antisense cDNA resulting from a genomic rearrangement involving the ARID1A gene in a primary breast carcinoma could transform NIH3T3 cells. During the course of our investigation, mutations in the ARID1A were reported to occur in up to 50% of ovarian clear cell carcinomas (Jones et al., 2010; Wiegand et al., 2010) . Thus ARID1A appears to show all of the hallmarks of a classical TSG (Presneau et al., 2003) .
We also report on ARID1A expression in human breast cancers. We found that low ARID1A RNA and/ or nuclear protein expression is associated with more aggressive breast cancer phenotypes. Finally, we found that ARID1A re-expression in the T47D breast cancer cell line results in significant inhibition of colony formation in soft agar. These results suggest that the ARID1A may be a TSG in breast cancer, and that it warrants further investigation as a potential diagnostic and therapeutic marker in breast cancer.
Results
NMD inhibition combined with genomic analysis identifies ARID1A as a potential candidate TSG in breast cancer A modification of a strategy described by Huusko et al. (2004) was used to identify transcripts with nonsense mutations. We inhibited NMD using emetine followed by inhibition of de novo transcription using actinomycin-D ( Supplementary Figures 1 and 2 ), in five breast cancer cell lines (MCF-7, MDA-MB-231, MDA-MB-361, MDA-MB-453 and T47D). Gene expression analysis comparing emetine-treated to untreated cells showed that the percentage of transcripts stabilized (that is, upregulated by two-fold) after drug treatment ranged from 8.5 to 10% of total transcripts in each of the five treated breast cancer cell lines.
To enrich for classical TSG candidates, genes showing an NMD ratio of >2 in emetine-treated versus untreated cell lines and mapping to regions of loss of heterozygosity (LOH) or homozygous deletions inferred by high-density, whole-genome SNP BeadChip analysis were identified. The percentage of total transcripts mapping to LOH regions with an NMD ratio >2 ranged from 1.4 to 4% of all transcripts (Supplementary Figure 2) . Reasoning that under-expression is a phenotype of classical TSGs, we then selected candidates showing levels of gene expression below the overall median value of expression for each cell line. Using this strategy, the number of candidates decreased to 0.6-1.9% of total transcripts depending on the cell line (Supplementary Figure 2) . To prioritize candidates for further analysis, we selected those genes, which showed an NMD ratio >2 uniquely in one of the five breast cancer cell lines. The rationale was based on the assumption that if one gene harbors a nonsense mutation in a given cell line, it would be very unlikely that the same gene would have a nonsense mutation in another cell line of a small sample set because of the very low frequency of nonsense mutations in tumor cells (Sjoblom et al., 2006) . Applying this selection strategy to all five breast cancer cell lines led to the selection of 53 candidate TSGs, or 0.03% of the total number of transcripts on this microarray platform (Supplementary Figure 1 and Table 1 ).
Sequencing of the 53 candidate genes was begun in the respective cell lines used for their selection. We began validating our list starting with genes that have been reported to possess potential tumor-suppressive function or to be involved in breast cancer. A total of 15 genes were sequenced before we found a nonsense mutation in CDH1 in the MDA-MB-453 cell line. CDH1 encodes cadherin-1 and is known to be mutated in the MDA-MB-453 cell line (Forbes et al., 2010) , a mutation, which was verified in our laboratory by DNA sequencing. CDH1 or cadherin is a well-known TSG, responsible for a hereditary cancer syndrome (Campeau et al., 2008) .
As Huang et al. (2007) reported that the ARID1A gene was genomically rearranged in a primary breast carcinoma, we also focused on the ARID1A gene in our list. We identified a nonsense mutation, c.944C>T, in exon-9 in the ARID1A gene, which introduces a premature stop codon at amino-acid position 944 ( Figure 1a) . We confirmed that the RNA levels of ARID1A were very low and increased when the T47D cell line was treated with emetine, the NMD inhibitor ( Figure 1b) . ARID1A is located at chromosomal band 1p36.11, mapping within the LOH region shown by the entire 1p arm in the T47D cell line (Figure 1c ). ARID1A encodes a human homolog of yeast SWI1, which contains a DNA-binding motif (AT-rich interactive domain, ARID). As this TSG candidate has not been extensively characterized, we further investigated its role as a putative TSG in breast cancer cells and tumors.
Genomic alterations involving ARID1A in primary breast cancers To determine whether the chromosomal region containing ARID1A is the target of genomic alterations in primary breast cancers, we analyzed 82 consecutive primary breast tumors by high-resolution aCGH and found that 11 (13%) of these tumor samples showed a DNA copy-number loss in the region overlapping the ARID1A locus on chromosome 1p36.11 (Figure 2b) . Sequencing of the protein-encoding exons of ARID1A in breast tumor samples showing DNA copy-number loss revealed no evidence of sequence variations.
ARID1A RNA expression in primary breast tumor samples To better understand the role of ARID1A expression in breast cancer, we studied the clinico-pathological factors associated with its gene expression in a well-annotated (Figure 3 ). These data suggest that ARID1A RNA expression is lower in highgrade, hormone-independent, HER2 þ and highly proliferative breast tumors, all of which have been shown to be indicators of more aggressive breast cancer phenotypes.
ARID1A RNA expression was also compared with the expression of a p53 signature gene set in the same data set. This gene set distinguishes tumors with a transcriptional fingerprint of p53 deficiency or low expression, thus potentially identifying not only tumors with p53 mutations, but also those harboring other forms of inactivation of p53 expression (for example, p53 methylation, MDM2 amplification). We found that ARID1A expression was significantly lower (Po0.001) in the p53-'deficient' tumors than in the p53 'wild-type' tumors ( Figure 3 ).
ARID1A protein expression in primary breast tumor samples As ARID1A functions as part of the SWI/SNF transcription-regulating complex, we expected that its expression in the nucleus would be important for TSG activity and that such expression would be higher in normal breast as compared with breast tumor tissues. We performed immunohistochemical analysis of ARID1A protein by using a tissue microarray (TMA) containing samples from 236 breast tumors, and matching normal breast tissues and adjacent preinvasive breast lesions from many of the patients. Nuclear staining was categorized into low (0 or 1 þ staining) or moderate/high (>1 þ staining). We observed a progressive decrease in the relative proportion of moderate/high nuclear staining as compared with (Figure 4a) . Indeed, only 37% of normal breast epithelial cells show low nuclear staining compared with 57% of ductal carcinoma in situ, 64% of invasive breast tumor cells and 80% of metastatic lymph nodes. This trend of progressively lower ARID1A protein nuclear expression corresponding to the various phases of breast tumor progression was significant using Spearman's rank correlation (r-value of À0.28, Po0.0001). By contrast, cytoplasmic staining of ARID1A protein was less intense across all lesions (data not shown). Thus ARID1A protein expression may be downregulated during breast tumor progression, or a selection of breast epithelial cells expressing lower nuclear protein levels may take place during tumor progression. We also found that nuclear ARID1A protein expression correlated with estrogen receptor (ER) and progesterone receptor (PR) positivity, and correlated inversely with histological grade and ER Table 2 ). These findings suggest that low/ absent nuclear protein levels are associated with more aggressive clinico-pathological features of breast tumors, and are consistent with our observations for ARID1A RNA expression.
To determine the prognostic significance of ARID1A protein expression, survival analysis was performed by using the nuclear staining score as above. In univariate analysis, patients with low nuclear protein staining had a trend with a two-fold higher risk of breast cancerrelated mortality (hazards ratio, 1.98; 95% confidence interval, 0.86-6.3; P ¼ 0.088).
Finally, many of the samples for which we had performed aCGH had tissue cores represented on this TMA. Nine of the 11 clinical samples with 1p36.11 DNA copy-number loss were represented on the TMA used for ARID1A protein expression analysis. We found that eight of these nine samples with DNA copy-number loss at 1p36.11 also had low levels of ARID1A nuclear protein expression, suggestive of a concordance between DNA copy-number loss and ARID1A protein expression.
ARID1A inhibits the growth of T47D breast cancer cells in soft agar
To assess the tumor-suppressive properties of ARID1A in vitro, we introduced a full-length ARID1A-expressing vector into T47D breast cancer cells. T47D breast cancer cells were stably transfected with the empty vector alone or with a full-length, sequence-verified ARID1A cDNA ( Figure 5 ). There was a significant difference in proliferation between ARID1A-transfected and empty vector-transfected T47D cells in culture (Supplementary Figure 3) . Importantly, ARID1A-transfected T47D cells were able to form significantly fewer colonies in soft agar than cells transfected with the empty vector ( Figure 5) .
Conversely, transfection of ARID1A small interfering RNA (siRNA) into the MCF-7 breast cancer cell line that expresses high levels of ARID1A resulted in a significant increase in proliferation in these cells (Supplementary Figure 4) . Taken together, these findings support a potential TSG function for ARID1A in breast cancer cells.
Discussion
We describe the application of an integrated genomic approach aiming at identifying candidate TSGs in breast cancer, which resulted in the discovery of an ARID1A gene mutation in the T47D breast cancer cell line. This approach is based on the manipulation of a homeostatic cellular process, NMD, whose function is to eliminate transcripts containing nonsense mutations. Such a manipulation enables the analysis of transcripts, which would otherwise not be present in tumor RNA, and therefore not be detectable using RNA-based tumor re-sequencing approaches. Once candidate NMD gene targets are uncovered, we performed whole-genome genotyping using SNP arrays in order to identify NMD target candidates located in regions of LOH or deletions. These criteria allowed us to enrich for 0.03-0.04% of all genes as candidate TSGs in five breast cancer cell lines. We obtained 9-13 top candidates per cell line, including CDH1, a gene known to contain a nonsense mutation in the MDA-MB-453 cell line in the Catalogue of Somatic Mutations in Cancer (COSMIC) database (Forbes et al., 2010) , validating our method of enriching for candidate TSGs. CDH1 is a known TSG, implicated in rare cases of hereditary diffuse gastric cancer syndrome, which also features lobular breast carcinomas (Campeau et al., 2008) . Somatic mutations in CDH1 have been reported in breast carcinomas (Berx and van Roy, 2009 ) and loss of function is thought to contribute to progression in cancer by increasing proliferation, invasion and/or metastasis (Strumane et al., 2004) .
A previously unreported nonsense mutation was identified in ARID1A in the T47D breast cancer cell line. Although somatic mutations were not identified in breast tumors harboring LOH of the ARID1A locus, mutation screening was limited to only 11 samples. However, we did find that both ARID1A gene and protein expression levels are related to clinico-pathological features of breast cancer, including hormone receptor status, tumor grade and p53 activation status. We showed that low ARID1A expression is associated with high tumor grade, p53 inactivation, and high Ki67 and ERBB2 RNA expression. We also showed that ARID1A expression significantly inhibits the ability of T47D breast cancer cells to form colonies in soft agar, and that its silencing by siRNA in highly expressing MCF-7 cells increases proliferation rates. Taken together, our data further support the notion of a tumorsuppressive function for ARID1A in breast cancer.
ARID1A encodes for AT-Rich interactive domaincontaining protein-1A and is a component of the SWI/ SNF chromatin-remodeling complex, which functions 
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A Mamo et al to regulate gene transcription as well as chromatin dynamics (Winston and Carlson, 1992; Carlson and Laurent, 1994; Hirschhorn et al., 1995; Kennison, 1995; Sudarsanam et al., 1999 Sudarsanam et al., , 2000 . During the course of this investigation, there were two independent reports of ARID1A mutations in 50% of endometroid ovarian carcinomas and 57% of clear cell ovarian carcinomas (Jones et al., 2010; Wiegand et al., 2010) . The COSMIC reports only four mutations in ARID1A: one each in central nervous system cancers, kidney cancers, lung cancers and skin cancers, but none in a variety of cancer types including 11 breast cancers (Forbes et al., 2010) . DNA copy-number changes of the 1p36 locus containing ARID1A were observed in 13% of breast tumors. Although associated with low ARID1A protein expression, these changes cannot account for all of the breast tumors showing low or absent ARID1A expression. Epigenetic inactivation of ARID1A expression may account for the apparent decreased expression of ARID1A RNA. Methylation silencing of the predicted CpG island overlapping the first exon of ARID1A as a possible mechanism of inactivation of gene expression requires further investigation (Dworkin et al., 2009; Orlando and Brown, 2009) . Although microRNAs targeting the 3 0 -untranslated region of ARID1A have been predicted by TargetScanS bioinformatic analysis (http://genome.ucsc.edu), to our knowledge none have been investigated as a possible mechanism for the under-expression of ARID1A.
There is an increasing body of evidence that several members of the SNF/SWI are implicated in different types of cancers (Rozenblatt-Rosen et al., 1998; Adler et al., 1999; Grand et al., 1999; Yuge et al., 2000; Biegel and Pollack, 2004; Medina and Sanchez-Cespedes, 2008; Roberts and Biegel, 2009 ), which suggests a role for chromatin remodeling in the pathogenesis of many cancers. Other members of the SWI/SNF complex besides ARID1A may affect ER-mediated transcription (Belandia et al., 2002) , as well as sensitivity to antiestrogens (Zhang et al., 2007) . The presence of a recognized DNA-binding domain in ARID1A and its demonstrated ability to bind to linear duplex DNA suggest that ARID1A contributes to the DNA binding activity in the SWI/SNF complex, although DNA binding through ARID regions is not restricted to AT-rich sequences, consistent with a wider range of DNA interactions for these proteins (Dallas et al., 2000) . The two ARID-containing proteins (ARID1A and ARID1B) are mutually exclusive subunits of the SWI/ SNF complexes, such that SWI/SNF complexes endowed with anti-proliferative properties contain ARID1A, whereas those endowed with pro-proliferative properties contain ARID1B (Nagl et al., 2007) . The anti-proliferative activity of ARID1A is underscored by the ability of ARID1A-containing SWI/SNF complexes to repress E2F1 (Van Rechem et al., 2009), Myc, cyclin-B2 and Cdc2 function (Nagl et al., 2006) . This is consistent with our finding that ARID1A RNA levels are significantly lower in high-Ki67-expressing breast tumors (Figure 2 ). More recent evidence also implicates ARID1A in the regulation of histone modifications, specifically in the targeting of histone H2B for ubiquitination (Li et al., 2010) , with consequent effects on E2F, histone deacetylase and Myc-dependent transcription.
Our study confirms that the ARID1A protein has the potential to play a tumor-suppressive role in the formation of breast cancer, and that its low expression is associated with more aggressive phenotypes of breast cancer such as high tumor grade, and with colony formation capacity in vitro in breast cancer cells carrying a nonsense mutation in this gene. These data add to the growing list of evidence supporting a critical role for SWI/SNF complex members in solid tumors such as breast cancer.
Materials and methods

Cell lines and breast tumors
Five breast cancer cell lines (MCF7, MDA-MB-231, MDA-MB-361, MDA-MB-453 and T47D) were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA) and tested for mycoplasma at reception and every 6 months thereafter using the Mycoplasma Detection kit (Invitrogen, Burlington, ON, Canada). Cells were maintained in RPMI supplemented with 10% fetal calf serum (Invitrogen) at 37 1C in a humidified incubator in 5% CO 2 . DNA was extracted from these cell lines by using the Qiagen DNAmp extraction kit (Qiagen, Germantown, MD, USA) according to the manufacturer's instructions. Three hundred consecutive breast tumors were collected as part of a tumor banking effort funded by the Fonds de la recherche en sante´du Que´bec tumor bank at the Centre Hospitalier de l'Universite´de Montre´al (CHUM) from 2000 to 2003. Patients had signed informed consent for breast tumor banking. One hundred of these tumor samples were used for DNA extraction. Tissue sections for each tumor showed >70% tumor cells as determined by a hematoxylin and eosin staining for each sample.
NMD assay of breast cancer cell lines NMD inhibition was performed as described previously (Huusko et al., 2004) and as shown in supplementary Figure  1 . Cell pellets were frozen and total RNA was extracted by using the RNeasy kit (Qiagen) in accordance with the manufacturer's instructions. Gene expression profiling was performed as reported previously (Hosein et al., 2010) . The ratio of individual transcript expression in emetine-treated versus untreated cells was determined at different time points. The NMD ratio used for analysis and selection of TSG candidates is the average of the ratios obtained per each of the four time points.
High-density SNP arrays of cell lines Genome-wide chromosomal abnormalities were inferred by the Infinium genotyping technology using Sentrix Human-1 BeadChip (Illumina, San Diego, CA, USA; http://www. illumina.com), performed at the McGill University and Genome Quebec Innovation Centre (Montreal, QC; gqinnovationcenter.com) . A 750-ng weight of DNA was used and the BeadChips were scanned by using the BeadArray Reader. Genotyping analysis was performed by using the BeadStudio software version 2.1, which provides an estimate of the allele frequency and copy number (log R ratio). LOH is inferred by (B) allele frequency where values deviating from 0.5 (less than 0.2 and greater than 0.6) indicate allelic imbalance or LOH. SNP information was based on NCBI Build 36.1 (www.ncbi.nlm.nih.gov/genome).
Mutation analysis of candidate TSGs
The genomic sequences of the entire coding region of each exon of each candidate TSG were obtained from the UCSC Santa Cruz Genome Bioinformatics Site (http://genome. ucsc.edu). All genomic positions correspond to UCSC Santa Cruz hg18 build 36 human genome sequence. Primer pairs for PCR amplification and sequencing of each coding exon were generated by using the Primer3 software (http://frodo.wi.mit. edu/cgi-bin/primer3/primer3_www.cgi). The primer pairs for ARID1A are provided in Supplementary Table 1 . Forward and reverse PCR primers were required to be located no closer than 50 bp to the target exon boundaries. Exons larger than 450 bp were analyzed as multiple overlapping amplicons. PCR products were designed to range in size from 300 to 700 bp, which was considered optimal for amplification, purification and sequencing. To minimize amplification of homologous genomic sequences, primer pairs were filtered by using the UCSC In Silico PCR software, and only pairs yielding a single product were used. PCR products were purified as recommended by the manufacturer (Qiagen) and DNA sequencing of products was performed at the McGill University and Genome Quebec Innovation Centre as well as at the TGEN DNA sequencing facility. Sequence chromatograms were aligned and analyzed with the Staden package (Staden et al., 2000) and the Mutation surveyor software Version 3.24 by using the reference sequence NM_006015.4.
Reverse transcription reactions of ARID1A
For semi-quantitative reverse transcription-PCR, cDNA was generated from 10 mg of total RNA extracted from breast cancer cell lines by using oligodT and SuperScript II reverse transcriptase (Invitrogen). The primers used for exon-9 of the ARID1A gene were 5 0 -TATATGCAGAGGAACCCCCAG AT-3 0 (forward reaction) and 5 0 -CATTGGGCAAGGCATTA TAGTT-3 0 (reverse reaction). PCR was performed at an annealing temperature of 60 1C and for 26 cycles. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was amplified simultaneously as a control for the efficiency of cDNA synthesis.
aCGH of breast tumors DNA was extracted from 14 frozen breast tumors by using the DNAamp kit (Qiagen), a subset of the 100 consecutively banked breast tumors that showed LOH as above. DNA quality was assessed on a 2100 bioanalyzer using a DNA 12000LabChip kit (Agilent Technologies, Palo Alto, CA, USA). aCGH was performed as reported previously (Hosein et al., 2010) .
Gene expression database analysis A published data set of 251 breast tumors profiled on both Affymetrix U133A and U133B arrays (Miller et al., 2005) was reanalyzed for this study. Briefly, microarray data were preprocessed by using the open source R statistical programming language (R development core team) and the RMA method as implemented in the Bioconductor affy Package (www.bioconductor.org). Data were preprocessed directly to Ensemble gene IDs (Dai et al., 2005) . For genes appearing on both array types, data were combined by calculating their median expression values from both arrays. ERBB2, Ki67 and PCNA status was estimated from the expression data itself. Tumor molecular subtype classification was performed based on the parameters described by Parker et al. (2009) . MannWhitney U-test was used to test the significance of the difference between the medians of two category phenotypes.
Immunohistochemistry
Immunohistochemical staining of ARID1A was performed by using a TMA slide set containing duplicate or triplicate 0.6-mm cores from 237 breast adenocarcinoma samples as well as pre-invasive lesions from the same surgical resection specimens, as described by Hassan et al. (2009) (Hassan et al., 2009) . We used the mouse monoclonal anti-ARID1A antibody (sc-81193; Santa Cruz, Santa Cruz, CA, USA) diluted 1/30 in blocking solution. Bound antibody was detected with goat anti-mouse biotin-conjugated secondary antibodies (2 mg/ml; Jackson ImmunoResearch Laboratories, West Grove, PA, USA). Two independent observers read the slides in a blinded manner (MB and OA). Only epithelial cells were evaluated and the result for each core was recorded separately. The average maximal staining intensity (no staining (0), low (1 þ ), moderate (2 þ ) or high (3 þ ) for each of two cores per sample) was recorded for each sample. Statistical analysis was performed according to Hassan et al. (2008) .
Generation of stable ARID1A-transfected T47D cell lines and siRNA transient transfection of MCF-7 cells The pCMV6-XL4 and pCMV6-XL4-ARID1A (catalog no. SC303719) vectors were purchased from OriGene Technologies (Rockville, MD, USA). The pIRES2-DsRed2 vector was provided by Dr Raquel Aloyz at the Segal Cancer Center. Antibodies against ARID1A (BAF250a; clone PSG3) and lamin-B (clone C-20) were purchased from Santa Cruz Biotechnology. Antibody against a-tubulin (DM1A) was obtained from Abcam (Cambridge, UK). Generation of the T47D polyclonal cell line stably overexpressing ARID1A was accomplished by co-transfection of the pCMV6-XL4-ARI-D1A expression plasmid and the pIRES2-DsRed2 plasmid in a ratio of 10:1 with the Lipofectamine LTX and PLUS Reagents according to the manufacturer's instructions (Invitrogen). Forty-eight hours after transfection, transfected cells were selected by treatment with 400 mg/ml geneticin (G418; Wisent, Quebec, Canada) and stably transfected cells were maintained in selection for subsequent passages at the same concentration of G418. Knockdown of ARID1A in MCF-7 cells was performed by transient transfection of 2.5 Â 10 5 cells in a 60-mm tissue culture dish with 12.5 ml (20 nM) of the control (CTL) or the human ARID1A siRNA (Hs_ARID1A_5), and 5 ml of the Attractene reagent according to the manufacturer's recommendations (Qiagen). Reduction efficiency was monitored by immunoblotting 72 h after siRNA transfection.
Protein extraction and immunoblotting
Stably T47D transfected cells were washed once in phosphatebuffered saline and nuclear extracts were obtained as described by Vallone et al. (1997) . Briefly, cells were resuspended in 10 volumes of homogenization solution and forced through a 26-gauge needle. The nuclei were then collected by centrifugation, resuspended and incubated for 12 h at 4 1C, centrifuged for 15 min at 12 000 r.p.m. and the supernatant was retained. The protease inhibitors aprotinin (10 mg/ml), leupeptin (10 mg/ ml), phenylmethylsulfonyl fluoride (1 mM), and the phosphatase inhibitors Na 3 VO 4 (1 mM) and NaF (5 mM) were added to both homogenization and extraction solutions. siRNA-treated MCF-7 cells were collected 72 h after siRNA transfection, washed in cold phosphate-buffered saline, resuspended in Kinexus lysis buffer (Kinexus, Victoria, BC, Canada) and incubated on ice for 15 min. Cell lysates were then centrifuged at 13 000 r.p.m. for 15 and the supernatants were collected. Protein concentration was determined by the Bradford protein assay (Coomassie Plus-The better Bradford assay reagent; Pierce, Rockford, IL, USA). Proteins from nuclear extracts (80 mg) were resolved by 8% sodium dodecyl sulfate-PAGE and transferred to nitrocellulose Hybond-C Extra membranes (Amersham Biosciences/GE Healthcare, Quebec, Canada). Western blotting and enhanced chemiluminescence detection were then performed according to the manufacturer's recommendations (Amersham Biosciences/GE Healthcare).
In vitro assays T47D cells stably transfected with pCMV6-XL4-ARID1A or the empty vector pCMV6-XL4 were seeded in a 96-well plate (5000 cells per well) in 200 ml of RPMI-1640 medium containing 10% fetal bovine serum. For the siRNA-treated MCF-7 cells, these cells were seeded in a 96-well plate (2500 cells per well) 72 h after siRNA transfection in 200 ml of Dulbecco's modified Eagle's medium high-glucose medium containing 10% fetal bovine serum. Twenty-four hours after seeding, the medium was changed and cell number was determined 5 days later by the Alamar Blue assay (Invitrogen) according to the manufacturer's instructions. For the soft agar growth assay, T47D cells (0.5 Â 10 4 ) stably transfected with pCMV6-XL4-ARID1A or the control empty vector were suspended in 1 ml of soft agar (0.30% Bactoagar in RPMI with 10% fetal bovine serum), plated onto 2 ml of solidified agar (0.70% Bactoagar in RPMI with 10% fetal bovine serum) in six-well plates and cultured for 1 month. Colonies were scored electronically using an automated cell colony counter (GelCount; Oxford Optronix, Oxford, UK).
